Celsentri® Tablets for CCR5‑Tropic HIV‑1 Treatment

What Celsentri® Is and How It Works

Celsentri® (maraviroc) is an oral antiretroviral used with other medicines to treat CCR5‑tropic HIV‑1 infection. It blocks the CCR5 co‑receptor on CD4 cells, which helps prevent HIV from entering the cell. You take Celsentri tablets by mouth, usually twice daily, as part of a combination regimen prescribed by your clinician. Many shoppers compare Celsentri price options to manage therapy costs, including Celsentri without insurance.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, and licensed pharmacists review every prescription before dispensing. We also work with vetted international partner pharmacies to source authentic brand medicines at competitive prices and maintain a broad selection.

Because Celsentri only works for CCR5‑tropic virus, a tropism test is required before starting. It is not effective against CXCR4‑tropic or dual/mixed‑tropic HIV‑1. Tablets can be taken with or without food. Your prescriber may adjust the dose if other drugs affect maraviroc metabolism.

Dosage and Usage

• Typical adult dose: 300 mg by mouth twice daily with other antiretrovirals.
• With strong CYP3A inhibitors (for example, ritonavir‑boosted protease inhibitors, cobicistat, ketoconazole): 150 mg twice daily may be used.
• With strong CYP3A inducers without an inhibitor (for example, efavirenz, rifampin, carbamazepine): 600 mg twice daily may be used.
• If both an inducer and inhibitor are present, 300 mg twice daily is often used. Follow your prescriber’s exact plan.
• Pediatric use is weight‑based; your clinician will select the tablet strength or oral solution as appropriate.
• Take tablets whole with water. Do not crush or split unless your prescriber directs.
• If you miss a dose and it is close to the next dose, skip the missed dose and resume the schedule. Do not double doses.
• Have a CCR5 tropism test before starting and if virologic failure occurs.
• Report dizziness or lightheadedness; Celsentri may cause postural hypotension in some patients.

• Store at 15–30 °C (59–86 °F) in a dry place, away from humidity.
• Keep tablets in the original container with the desiccant; close the cap tightly.
• Do not freeze. Protect from excessive heat above 30 °C (86 °F).
• Travel with your medication in your carry‑on. Keep in original labeled bottle for security.
• Use a reminder or pill organizer to maintain twice‑daily dosing across time zones.
• Avoid leaving tablets in a car or direct sunlight.
• Keep out of reach of children and pets.

Benefits and Savings

Celsentri is an entry inhibitor with a distinct mechanism. When used in a fully active regimen, it can reduce viral load and increase CD4 counts. Tablets are small, taken twice daily, and can be dosed with or without food, which supports adherence. Your prescriber can tailor the dose when needed due to drug interactions.

Ordering from a Canadian pharmacy can lower the Celsentri cost. Many patients report 60–80% savings compared with typical US pricing. If you pay cash, we can still help you compare options for Celsentri without insurance. Multi‑month supplies and bulk promotions may reduce the per‑month price, and you can set gentle reorder reminders in your account.

For current deals, see our Celsentri coupon page.

Side Effects and Safety

• Common effects: cough, upper respiratory symptoms, fever, rash, dizziness, headache.
• Gastrointestinal: nausea, diarrhea, abdominal pain, vomiting, loss of appetite.
• Musculoskeletal: joint or muscle pain, fatigue.
• Sleep or mood: insomnia, abnormal dreams.
• Blood pressure: lightheadedness or postural hypotension, especially at treatment start.
• Laboratory: elevated liver enzymes may occur in some patients.

Serious reactions are less common but need urgent attention. These include liver problems that may be preceded by rash, fever, or allergic features; severe skin reactions; significant dizziness or fainting; chest pain; and signs of infection. Postural hypotension risk is higher in severe renal impairment and with certain interacting drugs. Immune reconstitution inflammatory syndrome can occur when starting effective therapy. Review your full medication list with a pharmacist, as CYP3A inhibitors and inducers (for example, ketoconazole, clarithromycin, ritonavir‑boosted protease inhibitors, efavirenz, rifampin, carbamazepine, St. John’s wort) may require dose changes or avoidance.

Onset Time

Many patients see early viral load declines within 2–4 weeks after starting a fully active regimen that includes Celsentri. CD4 counts often begin to improve over the first 1–3 months. Your clinician will check labs and decide if the regimen is meeting goals. Full assessment usually spans several months, along with adherence support.

Compare With Alternatives

Integrase inhibitor–based therapy is common in initial treatment. Single‑tablet regimens such as Biktarvy® combine three drugs and are taken once daily. These are complete regimens and are not used with Celsentri, but they may be alternatives if appropriate for your treatment plan.

Non‑nucleoside reverse transcriptase inhibitors like Intelence® (etravirine) can be part of an optimized background regimen in certain cases. An NRTI backbone such as Descovy® (tenofovir alafenamide/emtricitabine) is commonly paired with other agents; your prescriber selects combinations based on resistance and drug interactions.

Entry inhibitor options differ. Maraviroc targets CCR5, while other agents such as ibalizumab or fostemsavir act at different steps. Your clinician may consider these if CCR5 tropism is absent or prior regimens have failed.

Combination Therapy

• Use Celsentri with other active antiretrovirals to create a fully suppressive regimen.
• Common backbones include two NRTIs selected by your prescriber based on history and resistance tests.
• Adjust the maraviroc dose when used with strong CYP3A inhibitors or inducers.
• Do not combine Celsentri with complete single‑tablet regimens intended as standalone therapy.
• If dizziness occurs, consider taking doses at times that reduce fall risk and discuss with your clinician.

Patient Suitability and Cost‑Saving Tips

Celsentri is for adults and certain pediatric patients with confirmed CCR5‑tropic HIV‑1. It is not recommended if your virus uses CXCR4 or is dual/mixed tropic. A tropism test is required before starting and if therapy fails. People with significant liver disease, cardiovascular disease, or a history of fainting should discuss risks and monitoring with their prescriber.

Severe renal impairment requires special caution, especially when strong CYP3A inhibitors or inducers are also used. Report any rash, jaundice, severe dizziness, chest pain, or signs of allergic reaction promptly. Pregnant or breastfeeding individuals should review benefits and risks with their care team.

To manage expenses, compare Celsentri online purchase options at Canadian pricing. Multi‑month supplies can lower the per‑month Celsentri cost, and occasional bulk promotions may help. Reorder reminders help you avoid gaps. If you pay the Celsentri cash price, you can still access the same Canadian savings seen by many patients who buy Celsentri online, including those considering Celsentri without insurance.

Authoritative Sources

US FDA Prescribing Information for Maraviroc (Celsentri)

Health Canada Drug Product Database: Maraviroc

Manufacturer information from ViiV Healthcare

Order Celsentri® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This content is for education and product information. It does not replace advice from your physician, pharmacist, or other qualified health professional.